Joseph W. Ramelli
Mr. Ramelli served as a director from August 2012 to December 2016. Prior to his appointment as chief executive officer, Mr. Ramelli worked as a consultant for several investment funds providing in-depth due diligence and investment recommendations on biotech companies. He has over 20 years of experience in the investment industry, having worked as both an institutional equity trader and as an equity analyst at Eos Funds, Robert W. Duggan & Associates and Seneca Capital Management. Mr. Ramelli graduated with honors from U.C. Santa Barbara, with a BA in Business Economics.
Mr. Emerson most recently served as the President and Chief Executive Officer of Symplmed Pharmaceuticals, which he had founded in 2013. He had led Symplmed to the submission, approval and commercial launch of PrestaliaR, and to the eventual sale of such assets to Marina Biotech in June 2017. He also spearheaded the development and launch of Symplmed’s DyrctAxess technology, a patented software designed to manage prescription fulfillment and patient monitoring. DyrctAxess has demonstrated a significant impact on patient conversion to treatment, long-term compliance and overall patient retention. Prior to founding Symplmed, Mr. Emerson served as the head of Commercial Development at XOMA from 2010 to 2013; and as Director of Marketing at Gilead Sciences from 2007 to 2010. He began his career at King Pharmaceuticals in sales, sales training and marketing. Mr. Emerson graduated from the University of Oregon with a Bachelor of Arts in Political Science with a specialization in Administration and Organization.
Seymour Fein, M.D.
Dr. Fein has been extensively involved in the successful development of over 20 drugs, biologics and medical devices leading to U.S. Food and Drug Administration (FDA) approvals. Dr. Fein began his career at Hoffmann-La Roche Ltd. as a senior research physician and was responsible for the clinical development program that led to approval of recombinant interferon-alpha for cancer treatment. Dr. Fein was also the medical director of Bayer Healthcare Pharmaceuticals (U.S.) where he was responsible for therapeutic areas including gastroenterology, oncology, and cardiology. He later served as medical director for Rorer Group (now part of Sanofi) and Ohmeda (now part of Baxter). Dr. Fein founded and has been managing partner of a clinical and regulatory consulting organization and has worked closely with the Division of Gastroenterology and Inborn Errors Products at the FDA. Dr. Fein has successfully overseen entrepreneurial drug development leading to the FDA approval of two orphan drug products in the field of gastroenterology. Dr. Fein received his B.A. degree from the University of Pennsylvania and his M.D. degree with honors from New York Medical College. He completed a three-year residency in internal medicine at Dartmouth and a three-year fellowship in medical oncology and hematology at Harvard Medical School, where he served as an instructor of medicine during his final fellowship year. Dr. Fein is board-certified in both oncology and internal medicine.
Larn Hwang, Ph.D
Dr. Hwang has served as the Chief Executive Officer of Oncotelic, Inc. since October 2015 and as the Chief Scientific Officer of Autotelic Inc. since October 2013. Dr. Hwang is a veteran in the drug development industry, with broad expertise in drug discovery and biomarker development, as well as clinical and regulatory operations. Dr. Hwang was a founder of IgDraSol, Inc. (which merged with Sorrento Therapeutics in 2013, where she later served as VP of Regulatory and Clinical Operations from September 2013 to May 2014) and served as its Chief Operating Officer from April 2012 to August 2013. She was a founder of Biomiga Diagnostics and served as its Chief Operating Officer from 2011 to August 2013. Prior to that, she served as Head of Cell Biology at Abraxis BioScience from November 2005 to June 2011 and as Senior Principal Scientist at Celgene Corporation from February 2011 to June 2011. Dr. Hwang made significant contributions to the field of antisense and miRNA with several patents applications filed on her work. Prior to that, Dr. Hwang held a position with Johnson & Johnson. Dr. Hwang received a Ph.D. in Molecular Microbiology from The University of Texas Southwestern Medical Center at Dallas.
Mr. Munsif has served as the Senior Vice President at Autotelic Inc. since November 2016, as the Senior Vice President of Portfolio Management of LipoMedics, Inc. since June 2016 and as the Senior Vice President of Portfolio Management of Oncotelic, Inc. since October 2015. Previously he served as the Chief Executive Officer of IthenaPharma Inc. from August 2016 until its merger with Marina Biotech in 2016, and as the Chief Operating Officer of IthenaPharma Inc. from September 2014 until August 2016. Prior to that, he served as Product Life Cycle Management and Supply Chain Consulting at Accenture from March 2013 until September 2014 and as Product Life Cycle Management and Supply Chain Management Operations at Herbalife from April 2009 until March 2013. Mr. Munsif received a M.S. in Industrial Engineering from the University of Oklahoma and a B.S. in Chemical Engineering from Manipal Institute of Technology.
Director of Business Development
Ms Falguni Trieu has served as the President and Founder of String Therapeutics since June 2010. String Therapeutics is developing therapeutic drug monitoring for the treatment of a variety of diseases and therapeutic options to counter the effect of aging. Ms Trieu has also served as the Business Director of Autotelic Inc. since January 2015 where she led global sourcing and business partnering with API manufacturers. Prior to that Ms Trieu served as the Marketing Director for Biomiga Diagnostics from July 2011 to November 2013. She has a BS in Microbiology with emphasis on oligonucleotide synthesis. She has numerous high profile publications in diabetes and has frequently presented at the World Congress on Controversies in Obstetrics, Gynecology & Infertility.